PURPOSE: To define tumor control and clinical outcomes of radiosurgery to marginal tumor doses of 12-13 Gy for unilateral acoustic neuroma patients. METHODS AND MATERIALS: Three hundred thirteen patients with previously untreated unilateral acoustic neuromas (vestibular schwannomas) underwent gamma knife radiosurgery between February 1991 and February 2001 with marginal tumor doses of 12-13 Gy (median, 13 Gy). Median follow-up was 24 months (maximum, 115 months; 36 patients with > or =60 months). Maximum doses were 20-26 Gy (median, 26 Gy), and treatment volumes were 0.04-21.4 mL (median, 1.1 mL). RESULTS: The actuarial 6-year clinical tumor control rate (no requirement for surgical intervention) for the entire series was 98.6 +/- 1.1%. Two patients required tumor resection; one had a complete resection for solid tumor growth and one required partial resection for an enlarging adjacent subarachnoid cyst. Six-year actuarial rates for preservation of facial nerve function, normal trigeminal nerve function, unchanged hearing level, and useful hearing were 100%, 95.6 +/- 1.8%, 70.3 +/- 5.8%, and 78.6 +/- 5.1%, respectively. The risk of developing trigeminal neuropathy correlated with increasing tumor volume (p = 0.038). CONCLUSIONS: Acoustic neuroma radiosurgery with doses of 12-13 Gy provides high rates of tumor control and cranial nerve preservation.
PURPOSE: To define tumor control and clinical outcomes of radiosurgery to marginal tumor doses of 12-13 Gy for unilateral acoustic neuromapatients. METHODS AND MATERIALS: Three hundred thirteen patients with previously untreated unilateral acoustic neuromas (vestibular schwannomas) underwent gamma knife radiosurgery between February 1991 and February 2001 with marginal tumor doses of 12-13 Gy (median, 13 Gy). Median follow-up was 24 months (maximum, 115 months; 36 patients with > or =60 months). Maximum doses were 20-26 Gy (median, 26 Gy), and treatment volumes were 0.04-21.4 mL (median, 1.1 mL). RESULTS: The actuarial 6-year clinical tumor control rate (no requirement for surgical intervention) for the entire series was 98.6 +/- 1.1%. Two patients required tumor resection; one had a complete resection for solid tumor growth and one required partial resection for an enlarging adjacent subarachnoid cyst. Six-year actuarial rates for preservation of facial nerve function, normal trigeminal nerve function, unchanged hearing level, and useful hearing were 100%, 95.6 +/- 1.8%, 70.3 +/- 5.8%, and 78.6 +/- 5.1%, respectively. The risk of developing trigeminal neuropathy correlated with increasing tumor volume (p = 0.038). CONCLUSIONS:Acoustic neuroma radiosurgery with doses of 12-13 Gy provides high rates of tumor control and cranial nerve preservation.
Authors: Niranjan Bhandare; Andrew Jackson; Avraham Eisbruch; Charlie C Pan; John C Flickinger; Patrick Antonelli; William M Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Douglas Kondziolka; Samuel M Shin; Andrew Brunswick; Irene Kim; Joshua S Silverman Journal: Neuro Oncol Date: 2014-09-28 Impact factor: 12.300
Authors: Andrew J Schumacher; Rohan R Lall; Rishi R Lall; Allan Nanney; Amit Ayer; Samir Sejpal; Benjamin P Liu; Maryanne Marymont; Plato Lee; Bernard R Bendok; John A Kalapurakal; James P Chandler Journal: J Neurol Surg B Skull Base Date: 2016-05-31
Authors: Mohamed H Khattab; Neil B Newman; David M Wharton; Alexander D Sherry; Guozhen Luo; Nauman F Manzoor; Alejandro Rivas; L Taylor Davis; Lola B Chambless; Albert Attia; Anthony J Cmelak Journal: J Neurol Surg B Skull Base Date: 2019-06-12
Authors: Yoichi Nonaka; Takanori Fukushima; Kentaro Watanabe; Allan H Friedman; Calhoun D Cunningham; Ali R Zomorodi Journal: Neurosurg Rev Date: 2016-01-19 Impact factor: 3.042
Authors: Benjamin J Arthurs; Wayne T Lamoreaux; Neil A Giddings; Robert K Fairbanks; Alexander R Mackay; John J Demakas; Barton S Cooke; Christopher M Lee Journal: World J Surg Oncol Date: 2009-12-18 Impact factor: 2.754